Pharma embraces imaging mass spec

“Drug developers are using the method to study drug distribution earlier in the discovery and development process”

c&en, 95 (23),  pp. 30-34, issue date: June 5, 2017

Celia Henry Arnaud

Sometimes it’s not enough to know how much drug has reached a particular tissue. Sometimes you need to know where in that tissue the drug has gone. To answer that and other questions, pharmaceutical companies are turning to imaging mass spectrometry. It allows pharma scientists to collect information about drug distribution much earlier in the discovery process than previously possible. The resulting pictures are helping drug developers prevent toxicity and off-target effects.

http://cen.acs.org/articles/95/i23/Pharma-embraces-imaging-mass-spec.html

Markus Stoeckli

Novartis Institutes for BioMedical Research in Basel

Leave a Reply